Medicover AB (publ)

OM:MCOV B Voorraadrapport

Marktkapitalisatie: SEK 26.5b

Medicover Toekomstige groei

Future criteriumcontroles 4/6

Medicover zal naar verwachting groeien in winst en omzet met respectievelijk 40.9% en 13.7% per jaar. De winst per aandeel zal naar verwachting groeien met 37.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 20% zijn.

Belangrijke informatie

40.9%

Groei van de winst

37.6%

Groei van de winst per aandeel

Healthcare winstgroei33.8%
Inkomstengroei13.7%
Toekomstig rendement op eigen vermogen20.0%
Dekking van analisten

Low

Laatst bijgewerkt15 Nov 2024

Recente toekomstige groei-updates

Recent updates

The Strong Earnings Posted By Medicover (STO:MCOV B) Are A Good Indication Of The Strength Of The Business

Nov 07
The Strong Earnings Posted By Medicover (STO:MCOV B) Are A Good Indication Of The Strength Of The Business

Here's What To Make Of Medicover's (STO:MCOV B) Decelerating Rates Of Return

Oct 24
Here's What To Make Of Medicover's (STO:MCOV B) Decelerating Rates Of Return

Investors Appear Satisfied With Medicover AB (publ)'s (STO:MCOV B) Prospects

Apr 22
Investors Appear Satisfied With Medicover AB (publ)'s (STO:MCOV B) Prospects

Additional Considerations Required While Assessing Medicover's (STO:MCOV B) Strong Earnings

Apr 04
Additional Considerations Required While Assessing Medicover's (STO:MCOV B) Strong Earnings

Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet

Mar 05
Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet

Medicover AB (publ)'s (STO:MCOV B) Intrinsic Value Is Potentially 31% Above Its Share Price

Feb 11
Medicover AB (publ)'s (STO:MCOV B) Intrinsic Value Is Potentially 31% Above Its Share Price

Returns On Capital At Medicover (STO:MCOV B) Paint A Concerning Picture

Dec 20
Returns On Capital At Medicover (STO:MCOV B) Paint A Concerning Picture

Does Medicover (STO:MCOV B) Have A Healthy Balance Sheet?

Dec 02
Does Medicover (STO:MCOV B) Have A Healthy Balance Sheet?

Medicover's (STO:MCOV B) Returns On Capital Not Reflecting Well On The Business

Sep 12
Medicover's (STO:MCOV B) Returns On Capital Not Reflecting Well On The Business

Medicover (STO:MCOV B) Has A Somewhat Strained Balance Sheet

Aug 21
Medicover (STO:MCOV B) Has A Somewhat Strained Balance Sheet

Is There An Opportunity With Medicover AB (publ)'s (STO:MCOV B) 37% Undervaluation?

Jun 12
Is There An Opportunity With Medicover AB (publ)'s (STO:MCOV B) 37% Undervaluation?

Medicover (STO:MCOV B) Will Want To Turn Around Its Return Trends

May 27
Medicover (STO:MCOV B) Will Want To Turn Around Its Return Trends

Is Medicover (STO:MCOV B) Using Too Much Debt?

May 12
Is Medicover (STO:MCOV B) Using Too Much Debt?

Returns On Capital At Medicover (STO:MCOV B) Have Hit The Brakes

Feb 16
Returns On Capital At Medicover (STO:MCOV B) Have Hit The Brakes

Is Medicover (STO:MCOV B) Using Too Much Debt?

Jan 30
Is Medicover (STO:MCOV B) Using Too Much Debt?

Is Medicover AB (publ) (STO:MCOV B) Potentially Undervalued?

Dec 30
Is Medicover AB (publ) (STO:MCOV B) Potentially Undervalued?

Estimating The Fair Value Of Medicover AB (publ) (STO:MCOV B)

Dec 17
Estimating The Fair Value Of Medicover AB (publ) (STO:MCOV B)

Medicover (STO:MCOV B) Might Have The Makings Of A Multi-Bagger

Oct 30
Medicover (STO:MCOV B) Might Have The Makings Of A Multi-Bagger

Does Medicover (STO:MCOV B) Have A Healthy Balance Sheet?

Oct 16
Does Medicover (STO:MCOV B) Have A Healthy Balance Sheet?

Should You Think About Buying Medicover AB (publ) (STO:MCOV B) Now?

Sep 09
Should You Think About Buying Medicover AB (publ) (STO:MCOV B) Now?

Estimating The Intrinsic Value Of Medicover AB (publ) (STO:MCOV B)

Jul 25
Estimating The Intrinsic Value Of Medicover AB (publ) (STO:MCOV B)

Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet

Jul 12
Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet

Investors Met With Slowing Returns on Capital At Medicover (STO:MCOV B)

Jun 13
Investors Met With Slowing Returns on Capital At Medicover (STO:MCOV B)

At kr179, Is It Time To Put Medicover AB (publ) (STO:MCOV B) On Your Watch List?

May 29
At kr179, Is It Time To Put Medicover AB (publ) (STO:MCOV B) On Your Watch List?

Winst- en omzetgroeiprognoses

OM:MCOV B - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/20262,72393573304
12/31/20252,37564112784
12/31/20242,07630452292
9/30/20241,99820122240N/A
6/30/20241,91123116225N/A
3/31/20241,82622113222N/A
12/31/20231,7461895205N/A
9/30/20231,682890205N/A
6/30/20231,610575202N/A
3/31/20231,548143186N/A
12/31/20221,5101230170N/A
9/30/20221,4893745182N/A
6/30/20221,4555967195N/A
3/31/20221,4428895205N/A
12/31/20211,377102115217N/A
9/30/20211,29993105202N/A
6/30/20211,2269091176N/A
3/31/20211,07652104176N/A
12/31/20209982683155N/A
9/30/20209301475141N/A
6/30/2020879453122N/A
3/31/20208841631100N/A
12/31/2019844232487N/A
9/30/2019796192879N/A
6/30/2019751193986N/A
3/31/2019709204085N/A
12/31/2018672223374N/A
9/30/2018643283475N/A
6/30/201862026N/A61N/A
3/31/201860023N/A55N/A
12/31/201758019N/A50N/A
9/30/201756010N/A40N/A
6/30/20175409N/A36N/A
3/31/20175226N/A31N/A
12/31/20164974N/A26N/A
12/31/20154168N/A29N/A
12/31/20143654N/A22N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei MCOV B ( 40.9% per jaar) ligt boven de spaarquote ( 1.2% ).

Winst versus markt: De winst van MCOV B ( 40.9% per jaar) zal naar verwachting sneller groeien dan de Swedish markt ( 15% per jaar).

Hoge groeiwinsten: De winst van MCOV B zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van MCOV B ( 13.7% per jaar) zal naar verwachting sneller groeien dan de markt Swedish ( 0% per jaar).

Hoge groei-inkomsten: De omzet van MCOV B ( 13.7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen MCOV B zal naar verwachting over 3 jaar laag zijn ( 20 %).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y